№ lp_2_3_06087
File format: docx
Character count: 4654
File size: 16 KB
This document is a notice announcing the award of multiple contracts for the provision of biologics and biologic implants to various contractors under the U.S. Department of Veterans Affairs.
Year:
2018
Region / City:
Fredericksburg, VA
Topic:
Biologics, Contracting, Medical Supplies
Document Type:
Contract Award Notice
Agency:
U.S. Department of Veterans Affairs
Author:
Not specified
Target Audience:
Contractors, Veterans Affairs
Period of Action:
From September 27, 2018
Approval Date:
September 27, 2018
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Emergency Use Treatment
Document Type:
Informed Consent Form
Year:
2019
Region / City:
Naas General Hospital
Topic:
Inflammatory Bowel Disease, Biologic Medication
Document Type:
Policy
Author:
Joanna Rea, Inflammatory Bowel Disease Clinical Nurse Specialist
Target Audience:
IBD CNSp, Gastroenterology team, nursing staff administering biologic medication
Approval Date:
14th January 2020
Revision Date:
January 2023
Version Number:
1
Supporting Evidence:
Infliximab, Remicade, Vedolizumab, Adalimumab, Imraldi, Amgevita, Hulio, Golimumab, Ustekinumab
Purpose:
Standardization of pre-screening and management of IBD patients requiring biologic treatment
Scope:
Biologic screening, patient education, IBD CNSp, gastroenterology team, nursing staff
Objective(s):
Ensure best practice for IBD patients on biologics
Outcome(s):
Clarity for staff on safe and evidence-based care for IBD patients on biologics
Governance:
IBD Working Group
Review Group:
Not Applicable
Date of Approval:
14th January 2020
Date of Next Revision:
January 2023
Year:
2025
Region / city:
UK
Topic:
Rheumatology, Axial Spondyloarthritis
Document type:
Guideline
Organization / institution:
British Society for Rheumatology
Author:
Sizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, Max Yates, Joe Eddison, Antoni Chan, Nick Clarke, Nadia Corp, Charlotte Davis, Lambert Felix, Kalveer Flora, William J Gregory, Gareth T Jones, Christopher A Lamb, Helena Marzo-Ortega, Daniel J Murphy, Harry Petrushkin, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Danielle A Van Der Windt, Dale Webb, Zenas Z N Yiu, Karl Gaffney
Target audience:
Health professionals, rheumatologists
Period of validity:
Ongoing
Approval date:
2025
Date of changes:
Not specified
Context:
This is a clinical guideline for treating axial spondyloarthritis with biologic and targeted synthetic DMARDs.
Year:
2026
Region / City:
United States, Silver Spring, MD
Subject:
Drug and Biologic Product Development
Document Type:
Meeting Package
Organization / Institution:
U.S. Food and Drug Administration (FDA)
Author:
Sponsor Investigator, MD, Professor, Department of University of California, Los Angeles
Target Audience:
FDA Reviewers, CBER/CDER Staff
Submission Date:
2026
Meeting Type:
INTERACT
Product Name:
Biologic XY
Product Description:
Adenoviral vector expressing human cDNA with 1 and 2 region deletions
Proposed Indication:
Treatment or prevention of specific disease or condition
Content Sections:
Introduction, Product Development Summary, Purpose of Meeting, Specific Questions, Supporting Data, Proposed Agenda, Sponsor Attendees, Suggested Dates, Meeting Format, References
Year:
2024
Region / City:
Not specified
Topic:
Dental treatment
Document Type:
Consent form
Organization / Institution:
MedPro Group Inc.
Author:
Not specified
Target Audience:
Patients receiving dental implant treatments
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Author:
Jonathan Ashmore
MRSE:
Gillian McNaught
Radiographer:
Heather Boylan
Authorisation date:
11/3/25 (NHS Scotland MR Physics group)
Review Date:
11/3/28
Note:
Version History
Type of document:
Procedure statement
Clinical context:
Orthopaedic implants are used to treat and support damaged bones and other structures, and the document covers the safety procedures for MRI scanning of internal orthopaedic implants.
Risk Assessment:
The document includes a risk assessment for MRI scanning of internal orthopaedic implants, outlining various risks and safety measures.
Period of validity:
From the authorisation date until the review date
Safety considerations:
Details the risks associated with MRI scanning of internal orthopaedic implants and offers a structured risk assessment for each type.
intended audience:
Medical professionals involved in MRI scanning of orthopaedic implants
Evidence review:
This section presents evidence supporting the adoption of Generic Implant Safety Procedures (GISPs) for MRI scanning of orthopaedic implants.
Discussion:
An optional section offering insights into the implementation and challenges of adopting GISPs.
Year:
2026
Region:
United States
Topic:
Health Insurance, Hearing Implants
Document Type:
Guidance Document
Organization:
Cochlear Americas
Author:
Cochlear Professional Resources Team
Target Audience:
Healthcare providers, patients seeking implantable hearing solutions
Coverage Focus:
Cochlear Implants, Baha® Systems
Key Processes:
Pre-certification, Pre-authorization, Appeals, Predetermination
Contact Information:
OMS Phone: (800) 633-4667 option 4, Email: [email protected]
Additional Resources:
Regional Reimbursement Experts, Coding Support Line
Year:
2015
Region / City:
Fredericksburg, VA
Subject:
Biological Implants, Procurement, Tissue Transplants
Document Type:
Agreement
Organization:
Department of Veterans Affairs
Author:
Strategic Acquisition Center
Target Audience:
Potential Offerors
Effective Period:
10 years (120 months)
Approval Date:
January 22, 2016
Modification Date:
N/A
Year:
2015
Region / City:
Wichita, Kansas
Topic:
Medical Technology, Cardiology
Document Type:
Press Release
Organization / Institution:
Wesley Medical Center
Author:
Susan Burchill
Target Audience:
General Public, Healthcare Professionals
Effective Date:
Oct. 19, 2015
Approval Date:
Oct. 19, 2015
Changes Date:
N/A
Year:
2021
Region / City:
Southampton, Nottingham, United Kingdom
Field:
Healthcare, Cochlear Implants, Telemedicine
Document type:
Research Article
Institution:
University of Southampton, University of Nottingham
Authors:
Helen Cullington, Padraig Kitterick, Mark Weal, Magdalena Margol-Gromada
Target Audience:
Researchers, Healthcare Providers, Clinicians
Duration of Study:
6 months
Date of Approval:
2021
Date of Last Update:
2021